BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30370569)

  • 1. Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial).
    Meunier ME; Neuzillet Y; Raynaud JP; Radulescu C; Ghoneim T; Fiet J; Giton F; Rouanne M; Dreyfus JF; Lebret T; Botto H
    Prostate; 2019 Feb; 79(3):272-280. PubMed ID: 30370569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sexual steroids in serum and prostatic tissue of human non-cancerous prostate (STERPROSER trial).
    Neuzillet Y; Raynaud JP; Radulescu C; Fiet J; Giton F; Dreyfus JF; Ghoneim TP; Lebret T; Botto H
    Prostate; 2017 Nov; 77(15):1512-1519. PubMed ID: 28905453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume.
    Pejčić T; Tosti T; Tešić Ž; Milković B; Dragičević D; Kozomara M; Čekerevac M; Džamić Z
    Prostate; 2017 Jul; 77(10):1082-1092. PubMed ID: 28594074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition.
    Shibata Y; Ito K; Suzuki K; Nakano K; Fukabori Y; Suzuki R; Kawabe Y; Honma S; Yamanaka H
    Prostate; 2000 Jan; 42(1):45-55. PubMed ID: 10579798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate.
    Drafta D; Proca E; Zamfir V; Schindler AE; Neacşu E; Stroe E
    J Steroid Biochem; 1982 Dec; 17(6):689-93. PubMed ID: 6184548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex relationship between sex hormones, insulin resistance and leptin in men with and without prostatic disease.
    Grosman H; Fabre B; Lopez M; Scorticati C; Lopez Silva M; Mesch V; Mazza O; Berg G
    Aging Male; 2016; 19(1):40-5. PubMed ID: 26526283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Measurement of T and DHT contents in normal and diseased human prostate tissues].
    Zhang Y; Ye L; Ding Q; Fang Z; Yao M; Shi D
    Zhonghua Wai Ke Za Zhi; 2000 Jul; 38(7):545-7. PubMed ID: 11832106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
    Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
    Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis.
    Madersbacher S; Schatzl G; Bieglmayer C; Reiter WJ; Gassner C; Berger P; Zidek T; Marberger M
    Urology; 2002 Nov; 60(5):869-74. PubMed ID: 12429318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of sex hormones in men with severe lower urinary tract symptoms and benign prostatic hyperplasia.
    Tan MO; Karabiyik I; Uygur MC; Diker Y; Erol D
    Int Urol Nephrol; 2003; 35(3):357-63. PubMed ID: 15160539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral and prostatic vein steroid concentrations in benign prostatic hypertrophy patients before and after removal of the adenoma.
    Lukkarinen O; Hammond GL; Kontturi M; Vihko R
    Scand J Urol Nephrol; 1980; 14(3):225-7. PubMed ID: 6163202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of sex hormone levels and risk of prostate cancer.
    Gann PH; Hennekens CH; Ma J; Longcope C; Stampfer MJ
    J Natl Cancer Inst; 1996 Aug; 88(16):1118-26. PubMed ID: 8757191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age, genetic, and nongenetic factors influencing variation in serum sex steroids and zonal volumes of the prostate and benign prostatic hyperplasia in twins.
    Meikle AW; Stephenson RA; Lewis CM; Wiebke GA; Middleton RG
    Prostate; 1997 Oct; 33(2):105-11. PubMed ID: 9316651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between oestradiol-17 beta, testosterone, dihydrotestosterone and 5 alpha-androstane-3 alpha, 27 beta-diol in human benign hypertrophy and carcinoma of the prostate.
    Ghanadian R; Puah CM
    J Endocrinol; 1981 Feb; 88(2):255-62. PubMed ID: 6162906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of radical prostatectomy on serum hormone levels.
    Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
    J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced prostate cancer is associated with a decrease in serum luteinizing hormone.
    Hilz H; Graefen M; Noldus J; Hammerer P; Knabbe C; Huland E; Huland H
    Eur Urol; 2000 Sep; 38(3):243-9. PubMed ID: 10940695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.